Contact

Partnership Inquiries

We are actively engaging with pharmaceutical companies interested in deploying steric-block LNA mixmer chemistry against extrahepatic RNA targets through our target-nomination design sprint.

anders@elenaetx.com
Anders M. Näär, PhD
Founder & CEO
Elenae Therapeutics
Bakar BioEnginuity Hub
2630 Bancroft Way
Berkeley, CA 94704
Bakar BioEnginuity Hub, UC Berkeley
Bakar BioEnginuity Hub, UC Berkeley
LinkedIn QR Code

What We Offer Partners

  • Target feasibility assessment and druggability scoring
  • AI-guided LNA mixmer library design and optimization
  • In vitro validation with dose-response characterization
  • In vivo PK/PD and tissue distribution in rodent models
  • Optimized lead candidates with preliminary CMC assessment
  • Accelerated target-to-lead timelines